 <h1>Alpelisib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to alpelisib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, alpelisib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking alpelisib:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>diarrhea</li>
<li>difficult, burning, or painful urination</li>
<li>dry mouth</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>frequent urge to urinate</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>rapid weight gain</li>
<li>stomach pain</li>
<li>sweating</li>
<li>tingling of the hands or feet</li>
<li>troubled breathing</li>
<li>unexplained weight loss</li>
<li>unusual tiredness of weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Pale skin</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of alpelisib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>decreased weight</li>
<li>dry skin or mouth</li>
<li>hair loss or thinning of hair</li>
<li>headache</li>
<li>heartburn</li>
<li>indigestion</li>
<li>loss or change in taste</li>
<li>stomach discomfort or upset</li>
<li>swelling or inflammation of the mouth</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alpelisib: oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphocyte count decreased (52%), hemoglobin decreased (42%), activated partial thromboplastin time (aPTT) prolonged (21%), platelet count decreased (14%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Severe hypersensitivity (e.g., anaphylaxis, anaphylactic shock, dyspnea, flushing, rash, fever, tachycardia)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Osteonecrosis of the jaw (ONJ)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Glucose increased (79%), hyperglycemia (65%), weight loss (27%), calcium (corrected) decreased (27%), glucose decreased (26%), potassium decreased (14%), albumin decreased (14%), magnesium decreased (11%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (10%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Gamma glutamyl transferase (GGT) increased (52%), alanine aminotransferase (ALT) increased (44%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonitis (including acute interstitial pneumonitis and interstitial lung disease)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (42%), lipase increased (42%), edema peripheral (15%), pyrexia (14%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions including laboratory abnormalities (all Grades, incidence 20% or greater) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, GGT increased, nausea, ALT increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, activated partial thromboplastin time (aPTT) prolonged, and alopecia.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%), dysgeusia/ageusia/hypogeusia (18%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (79%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., maculopapular, macular, generalized, papular, pruritic) (52%), alopecia (20%), pruritus (18%), dry skin/skin fissures/xerosis/xeroderma (18%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome (SJS), erythema multiforme (EM)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (58%), nausea (45%), stomatitis/aphthous ulcer/mouth ulceration (30%), vomiting (27%), mucosal inflammation (19%), abdominal pain/abdominal pain upper/abdominal pain lower (17%), mucosal dryness (12%), dyspepsia (11%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about alpelisib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: PI3K inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alpelisib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Piqray</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Breast Cancer, Male</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alpelisib: oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Lymphocyte count decreased (52%), hemoglobin decreased (42%), activated partial thromboplastin time (aPTT) prolonged (21%), platelet count decreased (14%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Severe hypersensitivity (e.g., anaphylaxis, anaphylactic shock, dyspnea, flushing, rash, fever, tachycardia)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Osteonecrosis of the jaw (ONJ)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Glucose increased (79%), hyperglycemia (65%), weight loss (27%), calcium (corrected) decreased (27%), glucose decreased (26%), potassium decreased (14%), albumin decreased (14%), magnesium decreased (11%)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (10%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Gamma glutamyl transferase (GGT) increased (52%), alanine aminotransferase (ALT) increased (44%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonitis (including acute interstitial pneumonitis and interstitial lung disease)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (42%), lipase increased (42%), edema peripheral (15%), pyrexia (14%)<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions including laboratory abnormalities (all Grades, incidence 20% or greater) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, GGT increased, nausea, ALT increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, activated partial thromboplastin time (aPTT) prolonged, and alopecia.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%), dysgeusia/ageusia/hypogeusia (18%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (79%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (e.g., maculopapular, macular, generalized, papular, pruritic) (52%), alopecia (20%), pruritus (18%), dry skin/skin fissures/xerosis/xeroderma (18%)</p><p><b>Uncommon</b> (0.1% to 1%): Stevens-Johnson syndrome (SJS), erythema multiforme (EM)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (58%), nausea (45%), stomatitis/aphthous ulcer/mouth ulceration (30%), vomiting (27%), mucosal inflammation (19%), abdominal pain/abdominal pain upper/abdominal pain lower (17%), mucosal dryness (12%), dyspepsia (11%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about alpelisib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: PI3K inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alpelisib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
<li>Breast Cancer, Male</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>